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magnitude of response is dependent on time points of 
evaluation. The predictive power of these changes on long 
term treatment outcome is object of ongoing prospective 
study. 
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Purpose/Objective: The scenario in cancer research is 
currently progressively moving on the analysis of established 
large database, realized by crossing and combining multiple 
data. These data must be analyzed by ad-hoc computer 
softwares to produce models that can predict the treatment 
outcomes in a reliable way. In order to make possible the 
integration and analysis of data from different cancer centers 
and cancer registries, to elaborate predictive models from 
large datasets there is the need of an 'ontology', a kind of 
dictionary that standardizes the medical terminologies. 
Materials and Methods: We defined the ontology evaluated 
by a multi-professional technical commission composed by a 
mathematician, an engineer, a doctor with experience in 
data storage, a programmer and a software expert. 
Results: More than 200 clinical, instrumental and imaging 
variables were cataloged and stored in three different levels. 
The first level (Registry Level) includes patient-related 
variables (age, sex, ethnicity, height, weight, etc.) that can 
be easily used for epidemiological analyzes. The second level 
(Procedure Level) includes data on the clinical presentation 
and pathology of the tumor, therapeutic procedures and their 
side effects. The third and final level (Research Level) will 
provide for the storage of data in advanced searches. In our 
ontology we preferably used concepts from existing and 
mature terminological systems (e.g. NCI Thesaurus, CTCAE, 
SNOMED-CT). We used field types as text, number, date, 
table, files. The chosen standard file formats were 'DICOM' 
for image and 'TXT files' for data treatment. The toxicity was 
stored with CTC4 scale and the RTOG scale (for back 
comparison with retrospective studies). 
Conclusions: A formal ontology is necessary to obtain a 
standardized and organized dataset. This allows to create a 
system to share and to analyze data from large multi-centers 
database. These data can be used to elaborate predictive 
models to tailored treatment in daily clinical practice.  
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Purpose/Objective: Descriptive analysis of high-risk 
neuroblastoma´s treated with volumetric modulated arc 
therapy (VMAT) based in 'SIOP-Europe 2011 high-risk 
neuroblastoma' guidelines. 
Materials and Methods: Based in International 
Neuroblastoma Staging System (INSS), we classify high-risk 
neuroblastoma those in stage 2, 3, 4 y 4S plus N-myc 
amplification, or stage 4 over one year-old. From september 
2010-2014 seventeen patients were treated with VMAT. 76.4% 
were boys and 23.6% girls, with a medium age of 37 months. 
N-myc amplification was positive in 47%. With INSS criteria, 
we noted:  
 
Stage (based in INSS) 
4 76.4%
3 11.8%
2 5.9% 
4S 5.9% 
Anatomical location 
Adrenal gland 64.7%
Abdominal 17.6%
Bilateral adrenal gland 5.8% 
Cervical 5.8% 
Thoraco-abdominal 5.8% 
 
After induction chemotherapy (COJEC), tumor exeresis and 
autologous blood marrow transplantation, all patients 
considered eligible for participation in this study were 
treated with VMAT (21 Gy maximum dose, fractioned over in 
14 sessions, 1,5 Gy each one) over the primary tumor area.  
Results: After medium folllow-up of 23 months (8-41), 41% 
are alive without tumor, 11.7% are alive with tumor, 23,5% 
have died because the tumor, 17.6% have died because an 
intercurrent cause, and 5.8% are dead by an unclearly 
cause.The radiotherapy tolerance was acceptable: 23.5% 
presented acute gastrointestinal toxicity grade 1-2 related to 
treatment. No chronicle toxicity has been noted.  
Conclusions: The N-myc amplification is clearly associated 
with major relapse risk and dead related with progression. 
This analysis revealed that VMAT in high-risk neuroblastoma´s 
treatment contributes to locoregional control with aceptable 
tolerance. There are no enough studies that compare VMAT 
with other techniques in high-risk neuroblastoma´s 
treatment. It is important the long follow-up of these 
patients to evaluate second neoplasms incidence, 
locorregional control and increase survival. 
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Purpose/Objective: Cancer is the most common cause of 
death at ages 1-16. Approximately 300 children annually 
develop a malignancy in Sweden and one third of these are 
brain tumors. Modern therapy cures 75% of all children struck 
with cancer. However, the tough therapy, including 
radiotherapy, has both acute and long-lasting, effects. Even 
low doses of ionizing radiation to the brain can cause 
intellectual impairment as well as perturbed growth and 
puberty.  
Hyperthermia has gained a reputation of effective radio- and 
chemo-sensitizer, which has minimal side effects. Our 
hypothesis is that the focused microwave hyperthermia will 
allow a reduced radiation dose with maintained treatment 
outcome and no added toxicity. A novel antenna applicator 
for microwave hyperthermia allowing treatment of deep 
brain tumors has been designed. The goal of this study is to 
investigate the feasibility of focused heating deep inside the 
head. 
Materials and Methods: The number and position of antennas 
was determined by using the homogeneous SAM (Specific 
Anthropomorphic Mannequin) head model. The focusing 
abilities of the resulting applicator were then investigated 
using a 13-year old patient model. Specific absorption rate 
(SAR) and temperature distributions were computed for five 
realistic tumors located at various sites. Both pre-operative 
and post-operative situations were considered. 
Results: The applicator consists of 16 antennas placed around 
the head in a helmet-like set-up and operates at a frequency 
range of 430-900 MHz. The antennas are attached to a 
parametric water bolus and aligned with the head shape. 
The results show considerable target coverage in terms of 
SAR in the target region with a remarkably low SAR in critical 
tissues in both pre- and postoperative cases. The 
postoperative situation showed more favorable heating of the 
target volume as exemplified by temperature distribution in 
meduloblastoma shown in Figure 1. The achieved median 
temperature was 42°C while for the preoperative cases, 
target temperatures were up to 3 degrees lower due to 
relatively high perfusion of the target.  
 
 
Conclusions: The newly designed system is capable of 
selective intracranial heating in postoperative scenarios. For 
preoperative applications, further improvements in heating 
techniques are currently investigated.  
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Purpose/Objective: For high risk abdominal neuroblastoma, 
traditional paediatric radiotherapy dogma dictates that an 
irradiated vertebral body (VB) should be fully included within 
the planning target volume (PTV) to ensure even dose 
distribution and avoid asymmetric growth. However, clinical 
experience indicates that beyond a threshold VB dose which 
abolishes or minimises growth, VB dose inhomogeneity is less 
relevant. Our objective was to assess whether dose painting 
using VMAT with a simultaneous integrated boost (SIB) can 
improve renal sparing.  
Materials and Methods: Five cases of lateralised disease 
previously treated with fixed-fields were replanned with dual 
arc VMAT using conventional (VMAT-conv) and SIB (VMAT-SIB) 
techniques. PTV21 was the original, unadjusted PTV (clinical 
target volume +1cm). Adjacent VB were taken as those ≤1cm 
from PTV21. For VMAT-conv, 21 Gy in 14 fractions was 
prescribed to PTV21 and adjacent VB. For VMAT-SIB, 21 Gy 
was prescribed to PTV21, but adjacent VB were constrained 
to < 20% dose gradient, or >15 Gy minimum. Organ at risk 
(OAR) dose constraints were from the SIOPEN HR-NBL-1 
protocol. Kidney doses were reduced iteratively to control 
